about
High-flux versus low-flux membranes for end-stage kidney diseaseHMG CoA reductase inhibitors (statins) for kidney transplant recipientsTreatment for peritoneal dialysis-associated peritonitisAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsInterventions for preventing bone disease in kidney transplant recipientsHaemodiafiltration, haemofiltration and haemodialysis for end-stage kidney diseaseAngiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseImmunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsThe effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysisStatins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trialsAldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trialsAn "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism.The number, quality, and coverage of randomized controlled trials in nephrology.Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials.Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials.Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review.Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials.Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.How to read a nephrology systematic review.Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease.Should we shift toward higher blood pressure targets in patients with chronic kidney disease?Renal growth factors: past, present and future.Primary cerebral lymphoma and membranous nephropathy: a still unreported association.Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy.How to read critically a prognostic cohort study.Sunset for statins after AURORA?Sevelamer: a promising but unproven drug.Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trialTaking aim at targetsHaemoglobin targets: we were wrong, time to move onENPP1 mRNA levels in white blood cells and prediction of metformin efficacy in type 2 diabetic patients: A preliminary evidenceOral mucosal lesions and risk of all-cause and cardiovascular mortality in people treated with long-term haemodialysis: The ORAL-D multinational cohort study.A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study
P50
Q24200387-F387D96D-37E0-47AF-B300-7653EBDC1BD0Q24241098-1EC9F1ED-255A-4D2C-8C79-252B744EED57Q24242227-A077F306-3260-48E7-8C1F-0A564918A34DQ24243124-237AC530-D344-4E6D-BE84-CDDCBDF306C3Q24243926-D28CBFF2-5345-4996-9A1B-25A406472EE4Q24244020-E952B3C1-9D4B-445D-A968-17DB1D8C560CQ24244197-4AE8C884-7AF6-4CB7-953F-A09FD244C4A2Q24245120-714007BC-00A1-4065-9DB2-548B1EBAA67CQ24245848-B8428525-A828-4407-9019-4C59CBB42668Q24604736-25E63408-9451-45B6-9430-F68E65B140A9Q33244366-F62F7F89-EC77-426C-8F84-3720B9FD0D67Q33414957-E76224ED-43FB-4A3B-A27D-77E8458B4019Q33888333-CB3368E9-43BB-49BD-B7F8-0440D175C8C6Q34201444-361D7A28-A12C-4F4F-BE77-A70DBCE6BD8AQ35640724-E5E25427-947E-40F8-9773-AD511D15C4E2Q35885198-6DDFB847-4F1C-4D83-80B6-70D64EBAF585Q35909898-054F4660-7C43-40EB-AE78-CB1AD5857281Q36064891-8EEFD633-A86C-4AFF-BF02-945C492394D4Q36167258-A297D567-C6B0-4964-BCDB-354F1FDFE011Q36294113-8F142039-B30A-42A7-9291-300BFF47CEF4Q36377628-CCA6095C-AB24-4A44-AC45-91A704AA9D59Q37013667-46CAAF9F-E21B-4E5C-9219-909C5DF4A54DQ37582606-5076961D-9C01-437B-AB41-3837BADBCF46Q37752508-1DD28DA8-692C-4D72-A9D4-A69025752A65Q37829891-BBD14150-6886-41DB-A8B0-581B614D83F5Q37953323-CBD25F4E-9035-4695-90FB-0579221AE465Q40816267-23796EDD-691D-4715-87D1-8218C801532CQ44015522-1028796C-C761-432E-BB21-D715339038BCQ45085869-0D29BD7F-9487-44D1-A992-31770B1F90EFQ45182500-3F31B44B-EA80-428D-BB0B-C739A6CF6C68Q46068711-71EBE3E8-14B9-4B4A-81A6-2BC4DAE91577Q46973992-FB19A331-2063-411E-A035-23D9FB9EDE69Q50138791-6F0D78FA-BABC-4167-BC31-6C8AFE1ABB29Q53201542-45893D1E-5594-44FA-A22E-1017FC83D7BAQ56992475-4B56A32D-50B0-4802-9EEF-B25FFA27B120Q59167698-18E2BB80-E6C0-490F-94E9-B54C2866EE92Q59167772-86D7D6CC-F3E7-4016-AA2B-B776BEEC2D45Q60050523-BF5B0E77-3A7E-4025-9E32-6A857113C5BBQ64980659-8FAD02A7-0415-4CE7-9AA2-006C9D0C74A3Q80392378-E6AD30B6-702B-412E-900E-136ECA5843CC
P50
description
researcher ORCID ID = 0000-0002-6936-0616
@en
wetenschapper
@nl
name
Giovanni Strippoli
@ast
Giovanni Strippoli
@en
Giovanni Strippoli
@es
Giovanni Strippoli
@nl
type
label
Giovanni Strippoli
@ast
Giovanni Strippoli
@en
Giovanni Strippoli
@es
Giovanni Strippoli
@nl
prefLabel
Giovanni Strippoli
@ast
Giovanni Strippoli
@en
Giovanni Strippoli
@es
Giovanni Strippoli
@nl
P106
P21
P31
P496
0000-0002-6936-0616